Johnson & Johnson (JNJ) gained after its earnings and raised guidance. One clear headwind facing the company's long-term: ongoing talc litigation. Arthur Wong, Healthcare Managing Director at S&P Global Ratings, believes the company is "making significant progress" in putting the "litigation to bed." Arthur sees potential in Johnson & Johnson when it comes to M&A and R&D outlook, but he explains his overall negative outlook on the stock.